Biotech
-
ASH24: Darzalex in smoldering myeloma, Merck’s ADC data and Novo’s sickle cell drug
J&J aims to expand Darzalex's use even further in the blood cancer, while Merck & Co. and Novo Nordisk presented…
Read More » -
BioAge shares tumble after decision to halt obesity drug study
The California biotech disclosed Friday plans to terminate a Phase 2 study testing azelaprag in combination with tirzepatide for weight…
Read More » -
Atlas doubles down on ‘disciplined’ biotech investing with latest fundraise
The venture firm’s “modest” $450 million fund, a lower total than some of its peers recently raised, reflects lessons learned after Atlas…
Read More » -
Janux impresses Wall Street with new prostate cancer drug results
While early and from a small trial, the findings suggest Janux’s method of “masking” T cell engagers could lead to…
Read More » -
Sarepta rebuilds drug pipeline with Arrowhead deal
A broad licensing and research alliance will hand Sarepta four clinical-stage candidates, while Arrowhead receives $500 million in cash and…
Read More » -
How Intra-Cellular surprised Wall Street by breaking character
The biotechnology company, which sees itself as "pretty conservative," recently put out an ambitious long-term revenue forecast for its schizophrenia…
Read More » -
Kronos, Idorsia plan layoffs; PTC shelves ALS drug
Kronos is cutting 83% of its workforce, while Idorsia is considering eliminating as many as 270 jobs. Elsewhere, PTC disclosed…
Read More » -
New data could help Merck expand use of cardiovascular drug
Positive results from a study of Winrevair could help the drugmaker achieve sales growth past top-seller Keytruda’s upcoming patent expirations…
Read More » -
Johns Hopkins surgeon Makary is Trump’s pick to lead FDA
A prolific medical research and author, Martin Makary criticized the FDA and CDC for their decision-making during the pandemic, although…
Read More » -
Biotech startups are built on venture capital. Track funding rounds here.
Venture capital firms incubate, grow and finance dozens of new drug companies each year. Follow the money they channel into…
Read More »